OnKure Therapeutics (OKUR) announced encouraging safety, tolerability, and pharmacokinetic data from the ongoing first-in-human trial of OKI-219, a potential best-in-class, mutant-selective PI3KalphaH1047R inhibitor. OKI-219 was well tolerated across all dose levels with no hyperglycemia, and only grade 1 treatment-related adverse events were reported. No dose interruptions, delays, reductions, or discontinuations were reported for any adverse events. OKI-219 dosed at 900 mg twice daily shows steady-state exposure levels with near-continuous coverage of the in vivo EC 80 for pAKT inhibition. These data are consistent with the Company’s preclinical data and support the continued development of OKI-219. Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models; Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKUR:
- OnKure Therapeutics initiated with an Outperform at Leerink
- OnKure Therapeutics Reports Strategic Merger and Financial Updates
- OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth
- OnKure files to sell 2.94M shares of Class A common stock for holders
- OnKure Therapeutics assumed with a Buy at H.C. Wainwright